27.32
前日終値:
$28.04
開ける:
$28.03
24時間の取引高:
301.07K
Relative Volume:
0.47
時価総額:
$1.74B
収益:
$32.87M
当期純損益:
$674.31M
株価収益率:
2.4049
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-9.24%
1か月 パフォーマンス:
+3.96%
6か月 パフォーマンス:
-53.74%
1年 パフォーマンス:
-17.01%
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AGIO
Agios Pharmaceuticals Inc
|
27.32 | 1.74B | 32.87M | 674.31M | -330.11M | 11.36 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-24 | 開始されました | H.C. Wainwright | Buy |
2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
2023-02-03 | 開始されました | Piper Sandler | Overweight |
2022-11-17 | アップグレード | Goldman | Sell → Neutral |
2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-12-03 | 開始されました | BofA Securities | Buy |
2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
2021-07-01 | 開始されました | Raymond James | Mkt Perform |
2021-06-10 | 開始されました | H.C. Wainwright | Buy |
2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
2020-03-04 | 開始されました | Barclays | Equal Weight |
2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
2019-05-23 | 再開されました | Goldman | Neutral |
2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
2018-05-23 | 開始されました | Citigroup | Buy |
2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
2018-02-15 | 繰り返されました | Needham | Buy |
2018-02-15 | 繰り返されました | SunTrust | Buy |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-08-10 | 繰り返されました | Needham | Buy |
2017-08-08 | 繰り返されました | SunTrust | Buy |
2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
2017-06-26 | ダウングレード | Janney | Buy → Neutral |
2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
2016-10-24 | 開始されました | Needham | Buy |
2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - The Manila Times
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages AGIO Shareholders to Contact the Firm - ACCESS Newswire
Alpha Thalassemia Market Trends, Growth Forecast & Treatment - openPR.com
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Scotiabank cuts Agios Pharma stock target to $71, keeps outperform rating - Investing.com UK
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times
Agios to Reveal Latest Rare Disease Therapeutic Advances at Major BofA Healthcare Conference - Stock Titan
Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) - Seeking Alpha
Agios (AGIO) Reports Lower Q1 Revenue as sNDA for Thalassemia Pr - GuruFocus
Agios Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals Shares Down After Q1 Net Loss Widens, Revenue Misses Estimates - marketscreener.com
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Earnings call transcript: Agios Pharm beats EPS expectations in Q1 2025 - Investing.com
Agios Q1 2025 slides: PYRUKYND sales dip QoQ, pipeline advances toward key catalysts - Investing.com
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals: Q1 Earnings Snapshot - MySA
Agios Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Loss of $-1.55, vs. FactSet Est of $-1.81 Loss - marketscreener.com
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - ADVFN
An Overview of Agios Pharmaceuticals's Earnings - Nasdaq
Long Term Trading Analysis for (AGIO) - news.stocktradersdaily.com
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for - MSN
BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating - marketscreener.com
Agios Pharmaceuticals (AGIO) Price Target Lowered by BofA but Buy Rating Maintained | AGIO Stock News - GuruFocus
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 | AGIO Stock News - GuruFocus
Agios Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Rare Disease Biotech Agios Sets Q1 2025 Earnings Call: Key Updates Expected May 1 - Stock Titan
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - The Manila Times
Anemia Market Set to Witness Significant Growth by 2032, Driven by Rising Awareness and Novel Oral Alternatives | DelveInsight - Barchart.com
Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com India
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com Australia
Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView
Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia
Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa
RBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO) - The Globe and Mail
Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says - MarketScreener
New Strong Sell Stocks for April 3rd - TradingView
Agios stock touches 52-week low at $27.12 amid market shifts - Investing.com India
Agios stock touches 52-week low at $27.12 amid market shifts By Investing.com - Investing.com South Africa
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):